NBIX Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$127.01 |
| 52 Week High | US$157.98 |
| 52 Week Low | US$107.84 |
| Beta | 0.35 |
| 11 Month Change | 9.97% |
| 3 Month Change | -13.42% |
| 1 Year Change | 13.02% |
| 33 Year Change | 43.89% |
| 5 Year Change | 12.67% |
| Change since IPO | 916.08% |
Recent News & Updates
Recent updates
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
Oct 10The Play On Neurocrine Biosciences
Oct 02Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
Aug 28Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Jul 09Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
May 08Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Apr 27Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt
Dec 11Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?
Sep 12We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease
Jun 08Shareholder Returns
| NBIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.5% | 3.7% | 5.7% |
| 1Y | 13.0% | 29.2% | 36.9% |
Return vs Industry: NBIX underperformed the US Biotechs industry which returned 29.2% over the past year.
Return vs Market: NBIX underperformed the US Market which returned 36.9% over the past year.
Price Volatility
| NBIX volatility | |
|---|---|
| NBIX Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NBIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NBIX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,700 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
Neurocrine Biosciences, Inc. Fundamentals Summary
| NBIX fundamental statistics | |
|---|---|
| Market cap | US$12.88b |
| Earnings (TTM) | US$385.90m |
| Revenue (TTM) | US$2.24b |
33.3x
P/E Ratio5.7x
P/S RatioIs NBIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBIX income statement (TTM) | |
|---|---|
| Revenue | US$2.24b |
| Cost of Revenue | US$716.20m |
| Gross Profit | US$1.53b |
| Other Expenses | US$1.14b |
| Earnings | US$385.90m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.81 |
| Gross Margin | 68.07% |
| Net Profit Margin | 17.21% |
| Debt/Equity Ratio | 0% |
How did NBIX perform over the long term?
See historical performance and comparison